Kidswell Bio Corporation · TSE:4584

Kidswell Bio — FY2024 Earnings Presentation

17 slides from Kidswell Bio's earnings presentation, May 13, 2025

1. Slide 1: Financial Results for FY 2024

   Biotech Striving for Value Creation Security Code： - For a Comprehensive Healthcare System for Children, Families, and Society - 4584 Financial Results for FY 2024 May 13, 2025 Kidswell Bio Corporation © 2025 Kidswell Bio Corporation. 1

2. Slide 2: Agenda

   ◆ Financial Highlights ◆ Business Highlights Agenda - Biosimilars Business - Cell Therapy Business (S-Quatre) ◆ Corporate Strategy and IR Activities © 2025 Kidswell Bio Corporation. 2

3. Slide 3: Financial Highlights

   Financial Highlights © 2025 Kidswell Bio Corporation. 3

4. Slide 4: Income statement

   Income statement Fiscal year 2023 Fiscal year 2024 Fiscal year 2024 (ending Mar 31, 2024) (ending Mar 31, 2025) Actual Actual Revised forecast Achieve Actual YoY （Unit：thousand yen） (non-consolidated) （consolidated） (consolidated) ment (non-consolidated) Net Sales 2,431,236 5,082,053 209% 4,900,000

5. Slide 5: Balance Sheet

   Balance Sheet （Unit：thousand yen） Fiscal year 2023 (non-consolidated) Fiscal year 2024 (consolidated) Current assets 4,924,221 6,700,570 （Cash and cash equivalents） 2,231,411 2,995,435 （Account receivables） 881,407 1,267,189 （Work in process） 875,654 1,475,092 （Advance payment） 739,567 819,857 （Prep

6. Slide 6: Future Business Outlook and Key Initiatives

   Future Business Outlook and Key Initiatives The forecast for net sales and operating income is presented in the form of a range, as a full-year projections for FY2025 remain under assessment pending greater clarity on the following strategic items: • Biosimilar production and delivery schedule • Cli

7. Slide 7: Business Highlights

   Business Highlights © 2025 Kidswell Bio Corporation. 7

8. Slide 8: Biosimilars Business

   Biosimilars Business © 2025 Kidswell Bio Corporation. 8

9. Slide 9: Planned Key Initiatives: Biosimilars (KWB)

   Planned Key Initiatives: Biosimilars (KWB) Initiatives FY2024 FY2025 Progress Maintaining stable supply through adjustments to the manufacturing schedule • Deliveries completed as scheduled and addressing deviations Marketed BS Manufacturing cost reduction measures • Margin improvements from FY2026

10. Slide 10: Cell Therapy Business (S-Quatre)

    Power of child’s stem cells to fight incurable diseases Cell Therapy Business (S-Quatre) S-Quatre Corporation Kidswell Bio Group © 2025 S-Quatre Corporation.

11. Slide 11: Planned key initiatives: Cell therapy (S-Quatre)

    Planned key initiatives: Cell therapy (S-Quatre) Initiative FY2024 FY2025 Progress Supporting clinical research at Nagoya • Status remained favorable at 24 weeks post-dosing (1st &2nd case) University for cerebral palsy • Drug product manufacturing is underway for administration(3rd case) • An inter

12. Slide 12: Execution of a new agreement with Mochida Pharmaceutical

    Execution of a new agreement with Mochida Pharmaceutical • Business development and commercialization agreement was signed with Mochida Pharmaceutical for SQ- SHED, proprietary stem cells derived from human exfoliated deciduous teeth, targeting pediatric cerebral palsy and traumatic brain injury in

13. Slide 13: Corporate Strategy and IR Activities

    Corporate Strategy and IR Activities © 2025 Kidswell Bio Corporation. 13

14. Slide 14: Corporate Strategy

    Planned key initiatives: Corporate Initiative FY2024 FY2025 Progress • Reviewing evaluation system in alignment with Restruction of corporate culture and FY2023 organizational restructuring Efficient systems • Promote the recruitment of human resources and utilization of optimized resource allocatio

15. Slide 15: IR Schedule for FY2025

    IR Schedule for FY2025 IR Basic Policy • Aiming to build trust and a strong relationship with the stock market, foster a better understanding of the company’s business among shareholders and investors, and achieve proper valuation through proactive communication, with an emphasis on the quality and

16. Slide 16: KIDS WELL, ALL WELL

    KIDS WELL, ALL WELL All for Kids, Kids for All © 2025 Kidswell Bio Corporation. 16

17. Slide 17: Disclaimer

    This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts, and assumpti

Kidswell Bio — FY2024 Earnings Presentation on 6ix